GLP-1s and Breastfeeding: What the New Lactation-Outcomes Trial Means for Postpartum Weight Loss

This article is for education only and does not constitute medical advice. It is not a substitute for professional evaluation by a licensed clinician. GLP-1 receptor agonists are not approved for use during pregnancy, and current labeling advises against their use while breastfeeding due to unknown effects on the infant. Whether any GLP-1 therapy is appropriate for your situation — before, during, or after lactation — is a decision that belongs with your prescriber, who knows your medical history and your infant's needs. This article makes no claim that GLP-1s are safe or unsafe during breastfeeding, provides no dosing guidance, and offers no outcome promises.

---

A new mother sits in her six-week postpartum checkup with two facts in tension. She has been cleared to resume normal activity. She is still carrying more pregnancy weight than she expected, and the metabolic readouts — glucose, lipids, blood pressure — are drifting in the wrong direction. Her clinician has mentioned that GLP-1 receptor agonists are, for most non-pregnant adults, among the most effective weight-management medications ever developed.

Then she mentions that she is breastfeeding, and the conversation changes. The prescribing label says avoid. The evidence base, if she searches it, says almost nothing. And the question she actually needs answered — what happens to my milk, and to my baby, if I take this? — has, until recently, had no human data at all behind it.

That gap is now being measured. A clinical trial launched at the University of Colorado is directly studying what happens to breastmilk production and composition when lactating mothers begin GLP-1 therapy.¹ This article explains what is currently known, what remains unknown, what the trial is designed to measure, and what questions postpartum patients should bring to their prescriber.

Why Postpartum Patients Ask About GLP-1s

Postpartum weight retention is not a cosmetic concern dressed up as one. Roughly half of gestational weight gain persists beyond six months in a substantial proportion of mothers, and that retained weight compounds: each successive pregnancy adds cumulative metabolic load, raising the long-term risk of insulin resistance, hypertension, and type 2 diabetes. For women who entered pregnancy with overweight or obesity — or who developed gestational diabetes — the postpartum window is a high-leverage point for intervention. What happens in the first year after delivery shapes metabolic trajectory for a decade.

GLP-1 receptor agonists — semaglutide, tirzepatide, and the dual agonists now entering the market — have reset expectations for what pharmacological weight management can do. Average trial reductions of 15% to 22% of body weight are not a marginal improvement over prior medications; they are a different category of result. A postpartum patient who read those numbers, who is managing the physical reality of an infant and the metabolic reality of retained weight, will reasonably ask: can I use this now?

The honest answer, as of this writing, is: we do not fully know, and the reason we do not know is a data gap, not a confirmed danger or a confirmed safety. That distinction matters. "Unknown" is a statement about the state of evidence. It is not a synonym for "safe," and it is not a synonym for "dangerous." It means the study has not been done — until now.

What Is Currently Known — and What Is Not

What the labels say

The FDA prescribing information for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) states that the drugs should be avoided during breastfeeding.² The reason given is consistent across labels: there are no data on the presence of the drug in human milk, on the effects on the breastfed infant, or on milk production. This is a precautionary position, and it is important to understand what kind of statement it is. A precautionary recommendation reflects absence of evidence, not evidence of harm.

The labels also recommend discontinuing these medications at least two months before a planned pregnancy, because of findings in animal reproductive studies. That recommendation applies to pregnancy planning, not lactation — but it signals how cautious the regulatory posture is around these drugs and reproductive windows generally.

What the human data actually show

Almost nothing. There is no published, controlled human study measuring semaglutide or tirzepatide transfer into breastmilk, no study measuring infant exposure, and no study systematically tracking lactation outcomes — milk volume, milk composition, infant growth — in mothers using these drugs.

What exists is indirect. Animal lactation studies in rats have detected semaglutide in milk, though rodent milk composition, receptor pharmacology, and infant metabolism differ from humans in ways that limit how much those findings can be extrapolated. Pharmacokinetic modeling suggests that large peptide-based drugs have low expected oral bioavailability in an infant's gut — but "low expected" is a modeling statement, not a measurement, and infant gut permeability in the early months differs from adult assumptions.

On the milk-supply side, the concern is more direct: GLP-1s suppress appetite, and caloric deficit is a well-documented driver of reduced milk production. A lactating mother who loses weight rapidly on a GLP-1 may see milk volume fall — not necessarily because of the drug itself, but because of the energy deficit the drug induces. Separating those two causes is one of the hardest problems in this research area, and it is precisely the problem the new trial is designed to address.

What the evidence gap means in practice

In practice, the gap means that when a postpartum patient asks her prescriber whether she can start a GLP-1 while breastfeeding, the prescriber is working without the data they would normally use to answer. They can tell the patient what the label says. They can explain the pharmacological reasoning. They cannot point to a study of lactating humans. That is an uncomfortable position for a clinician, and it is a frustrating one for a patient.

It is also, increasingly, a common one. Postpartum GLP-1 use is among the most frequent real-world off-label scenarios in metabolic medicine today. The question is being asked in exam rooms across the country — in Dallas–Fort Worth, in Denver, in every market where these medications are prescribed — and until now, the honest answer has been a shrug backed by a precautionary label.

What the New Trial Measures — and Why It Matters

The University of Colorado study, registered as NCT07720414, is titled "Effects of GLP-1 RAs on Human Lactation Outcomes."¹ It is a prospective observational cohort study, currently recruiting, with an estimated enrollment of 18 lactating mothers. The design is careful: researchers measure breastmilk production volume and macronutrient composition — including milk fat — before participants begin an injected GLP-1 receptor agonist or dual agonist, and then again after initiation, over a follow-up period of roughly 2.5 to 4.5 months.

The core questions

The trial addresses two questions that current guidelines cannot answer:

Does GLP-1-induced weight loss change milk production? Participants express milk during morning study visits using a study-provided breast pump, allowing researchers to quantify hourly milk production rate before and after drug initiation. Weight loss is confirmed with seven-day body weight averages, so the analysis can distinguish changes in milk output that track with caloric deficit from changes that appear drug-specific.

Does GLP-1 use alter the nutritional composition of milk? Milk samples are analyzed for macronutrient content — fat, protein, carbohydrate. If a mother loses weight on a GLP-1 and her milk's caloric density changes, that has implications for infant nutrition that no amount of pharmacological reasoning can settle. It has to be measured.

The design choices that matter

Several features of the trial design deserve attention, because they speak to why this question has been so hard to study:

• Observational, not interventional. Participants are prescribed GLP-1 therapy by their own clinicians as part of normal care; the study observes what happens to their milk. This is the ethical structure required when studying a population for whom the drug is not approved — researchers cannot randomize lactating mothers to a drug that labels advise against.
• Injected formulations only. The inclusion criteria specify subcutaneous GLP-1 receptor agonists, excluding oral formulations. The study authors note that oral GLP-1s contain absorption enhancers that may drive drug accumulation in milk — a detail that reflects how carefully the pharmacological reasoning has been done.
• Small N, high signal. Eighteen participants is a small cohort. It is enough to detect large effects on milk volume or composition, but it will not answer subtler questions — for example, whether effects differ by maternal BMI, by infant age, or by dose. Larger confirmatory studies would follow if the signal warrants them.

What the results could change

The trial's results matter in both directions. If milk volume and composition are unaffected — or if reductions track purely with caloric deficit, something addressable through nutritional support — the finding would open a large patient population to a therapy currently closed to them by precautionary labeling. If milk production is suppressed in ways that exceed what caloric deficit explains, or if composition shifts in ways that compromise infant nutrition, the finding would strengthen the existing contraindication with actual data.

Either outcome is more useful than the current state. Guidelines built on absence of evidence are guidelines that different clinicians will apply differently — some erring toward strict avoidance, others weighing maternal metabolic risk against theoretical infant risk. Data replace discretion with measurement. That is what this trial begins to do.

It will not be fast. The estimated completion date is mid-2028. Interim observations may surface sooner, but postpartum patients asking the question today should understand that a definitive answer is years away — and that any decision made in the interim is being made under clinical judgment, not under trial evidence.

What to Ask Your Prescriber

If you are postpartum, breastfeeding, and considering GLP-1 therapy, the following questions structure a productive conversation with your prescriber. They are not a script for obtaining a prescription. They are a way to make sure the decision — whatever it is — is made with your full situation in view.

1. Given my postpartum timeline, my metabolic labs, and my breastfeeding goals, what are my options — including non-pharmacological ones? GLP-1s are not the only route to postpartum weight management. Structured nutrition programs, progressive exercise protocols appropriate to postpartum recovery, and in some cases metformin or other agents with longer lactation track records may be appropriate. A clinician who knows your labs and your history can weigh these against a GLP-1 with an unknown lactation profile.

2. If I am not a candidate for a GLP-1 while breastfeeding, what is the timeline for reassessment? For many mothers, lactation is a defined window — six months, twelve months, longer. A specific reassessment plan converts an indefinite "not now" into a structured "here is when we revisit." Ask what markers would need to look like, and when.

3. What should I know about the difference between the labeling guidance and the current evidence? A good prescriber will explain the distinction between a precautionary label and a demonstrated harm — and will be honest about the limits of what they can tell you. If the conversation does not include that nuance, it is worth seeking a second opinion.

4. If I have been on a GLP-1 and am now pregnant or planning pregnancy, what does that change? This is a different but related question, and it has clearer guidance: the labels recommend discontinuing at least two months before a planned pregnancy. If this is your situation, raise it directly.

5. Who else should be involved in this decision? Depending on your situation, your infant's pediatrician may have relevant input — particularly regarding infant growth monitoring if any therapy is being considered. Ask whether a coordinated conversation makes sense.

For patients in the Dallas–Fort Worth area, LuxeFit Wellness provides in-person consultations where these questions can be worked through with a licensed clinician who knows the Texas telemedicine and peptide-therapy landscape. Patients elsewhere can use our guide to evaluating a telemedicine peptide provider to understand what a legitimate remote program looks like — and what questions to ask before your first consultation.

The Bigger Picture

The GLP-1 lactation question is a small trial with an outsized footprint. Postpartum patients are asking it in large numbers, the current answer is built on absence of data rather than presence of evidence, and the first systematic measurement is now underway. What the field does with the results — whether they expand access or harden the contraindication — will affect a population of mothers who are, right now, being told "we don't know" by well-meaning clinicians who have nothing better to offer.

That is not a failure of medicine. It is how medicine is supposed to work: identify the gap, design the study, measure the outcome. The trial at the University of Colorado is the first step in that sequence. The postpartum patients asking the question today are, in a real sense, the reason it exists.

For more on how GLP-1s interact with reproductive health — including preconception planning, PCOS, and perimenopausal metabolic changes — see our guide for OB-GYN patients. And if you are new to peptide and GLP-1 therapy generally, our three questions to ask before your first peptide consultation covers the fundamentals of evaluating any provider before you commit.

---

Frequently Asked Questions

Is it safe to take a GLP-1 while breastfeeding?

This article makes no claim that GLP-1s are safe or unsafe during breastfeeding, in either direction. Current prescribing labels advise against use during lactation because there are no data on drug transfer into breastmilk or effects on the infant. That is a precautionary position based on absence of evidence, not a demonstrated harm. Whether any medication is appropriate for your situation while breastfeeding is a decision for your prescriber, who can weigh your metabolic health, your infant's needs, and the available alternatives.

Is there any research on GLP-1s and breastmilk?

Until recently, essentially none in humans. A prospective observational study at the University of Colorado (NCT07720414) is now recruiting lactating mothers to measure breastmilk production volume and macronutrient composition — including milk fat — before and after beginning an injected GLP-1 receptor agonist or dual agonist.¹ It is the first study designed to directly address this evidence gap. Results are not expected before the late 2020s.

Will a GLP-1 affect my milk supply?

Unknown in humans. GLP-1s reduce appetite, and caloric deficit is a known driver of reduced milk production — so weight loss on a GLP-1 could reduce supply indirectly. Whether the drug itself has an effect on milk production, independent of caloric deficit, is exactly what the University of Colorado trial is designed to measure.¹ If you are breastfeeding and experiencing supply concerns, discuss them with your pediatrician or a lactation consultant before making any medication decisions.

What do I do if I want to lose postpartum weight but am breastfeeding?

Bring the question to your prescriber. There are structured, non-pharmacological approaches to postpartum weight management — nutrition programs, exercise protocols appropriate to postpartum recovery, and in some cases medications with longer lactation track records — that a clinician can tailor to your situation. This article does not recommend for or against GLP-1 use during lactation. It exists to explain the evidence gap and the questions worth asking.

How long will it be before we have an answer?

The University of Colorado trial has an estimated completion date of mid-2028.¹ Interim findings may be published earlier, but a definitive, guideline-shaping answer is years away. Any decision made in the interim is a clinical judgment call, not an evidence-based determination.

---

References

---

---

LuxeFit Wellness is a cash-pay wellness clinic serving the Dallas–Fort Worth area and patients nationwide through telemedicine. This content is educational only and does not constitute medical advice. It contains no patient testimonials, provides no dosing guidance, makes no safety claims in either direction regarding GLP-1 use during lactation, and offers no outcome promises. Decisions about GLP-1 therapy during any reproductive window — including lactation — belong with a licensed clinician who knows your medical history.

You built it. We optimize it.

Related Reading

• GLP-1s and Reproductive Health: What OB-GYN Patients Should Know
• Three Questions to Ask Before Your First Peptide Consultation
• Telemedicine Peptide Therapy in Texas: How Virtual Care Works